News

30.12

EDDING Group and Genor Bio have completed the merger

05.07

EDDING Announces NMPA Approval Of VASCEPA® (Icosapent Ethyl) For New Cardiovascular Risk Reduction (CVRR) Indication in Mainland China

15.11

NMPA Accepts Marketing Application for VASCEPA® (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication

29.06

EDDING Recives Regulatroy Approval For MULPLETA® (Lusutrombopag Tablets) in Mainland China

01.06

EDDING Receives Regulatory Approval For VASCEPA® (Icosapent Ethyl) in Mainland China

16.01

Lusutrombopag Phase III Study Results in Mainland China was published on Hepatology International